In 2012, Biotech IPOs Continue Their Inside Story
This article was originally published in Start Up
Executive Summary
Among the new realities for life science VCs, from structured acquisitions to no-go therapeutic areas, it looks like we can add insider participation in IPOs to the list. It's been nearly a year since a life-science company went public in the US without its private investors pitching in.